Ravulizumab clinical trials
Ravulizumab is named as an intervention in 14 current clinical trials in our Italy, Japan, USA, China, Poland, Germany, Spain, South Korea, France, Canada, Taiwan, UK, Austria, Czechia, Brazil, Australia, Netherlands, Belgium, Turkey, Israel, Portugal and Switzerland registers. 10 are recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is Alexion Pharmaceuticals, Inc (10). The most-studied condition is Generalized Myasthenia Gravis.
Where Ravulizumab is approved
All regulators →Of the three regulators tracked here, the first to approve Ravulizumab was the US, on 21 Dec 2018. It is approved in 3 of the 3 regulators tracked here.
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
What health systems spend on Ravulizumab
All medicines →From NHSBSA Prescription Cost Analysis (Open Government Licence v3.0) and CMS State Drug Utilization Data. Both are gross amounts: neither system publishes its discounts or rebates per drug. Products combining several substances are not counted here.
How Ravulizumab works
All drug targets →- Complement C5 inhibitor InhibitorTarget: C5 complement C5ChEMBL only
- IgA glomerulonephritisPhase 3
- Acute kidney injuryPhase 3
- Acute lung injuryPhase 3
- Acute respiratory distress syndromePhase 3
- Amyotrophic lateral sclerosisPhase 3
- Atypical hemolytic-uremic syndromePhase 3
- Myasthenia gravisPhase 3
- Neuromyelitis opticaPhase 3
- PneumoniaPhase 3
- Thrombotic microangiopathyPhase 3
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL3989986, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 10168, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
NICE appraisals of Ravulizumab
All NICE appraisals →NICE, which decides whether the NHS in England should fund new medicines, has published 4 technology appraisals of Ravulizumab. 4 are current, and 2 of these recommend it for at least some patients.
| Appraisal | NICE recommendation | Published | Status |
|---|---|---|---|
| Ravulizumab for treating generalised myasthenia gravis (terminated appraisal) NICE TA940 | Terminated (no company submission) | 20 Dec 2023 | Current |
| Ravulizumab for treating AQP4 antibody-positive neuromyelitis optica spectrum disorder (terminated appraisal) NICE TA941 | Terminated (no company submission) | 20 Dec 2023 | Current |
| Ravulizumab for treating atypical haemolytic uraemic syndrome NICE TA710 | Recommended | 23 Jun 2021 | Current |
| Ravulizumab for treating paroxysmal nocturnal haemoglobinuria NICE TA698 | Recommended | 19 May 2021 | Current |
NICE decisions apply to the NHS in England. In Ireland the HSE decides on reimbursement, advised by the National Centre for Pharmacoeconomics. Titles, categories and dates link to the guidance on nice.org.uk. © NICE 2026 technology appraisal guidance. Available from www.nice.org.uk/guidance. All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.
Patient leaflets for Ravulizumab
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- IEIreland: 2 products on the HPRA listEach product record links to the HPRA, which publishes the leaflet and SmPC.
- EUEuropean Union: UltomirisEMA product information: package leaflet and summary of product characteristics in every EU language.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of Ravulizumab
14 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Ravulizumab across our data
Ireland · EU · USThe same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
Licensed in Ireland (HPRA)
2 single-substance products containing Ravulizumab on the HPRA medicines list.
- Ultomiris 1 100 mg/11 mL concentrate for solution for infusionAlexion Europe S.A.S. · EU/1/19/1371/003
- Ultomiris 300 mg/3 mL concentrate for solution for infusionAlexion Europe S.A.S. · EU/1/19/1371/002
Supply shortages
No entry for Ravulizumab in the EMA, FDA or German BfArM shortage lists we track.
Conditions studied with Ravulizumab
16 conditionsAll 16 conditions
| Condition (as registered) | Trials |
|---|---|
| Generalized Myasthenia Gravis | 4 |
| gMG | 3 |
| Immunoglobulin A Nephropathy | 2 |
| IgAN | 2 |
| Neuromyelitis Optica Spectrum Disorder | 2 |
| NMOSD | 2 |
| Atypical Hemolytic Uremic Syndrome | 2 |
| Delayed Graft Function | 1 |
| DGF | 1 |
| Kidney Transplant | 1 |
| IgAVN | 1 |
| Immunoglobulin A Vasculitis Associated Nephritis | 1 |
| Anti-AChR Antibody Positive | 1 |
| Myasthenia Gravis, Generalized | 1 |
| Paroxysmal Nocturnal Haemoglobinuria | 1 |
| aHUS | 1 |
Sponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Alexion Pharmaceuticals, Inc | 10 |
| AstraZeneca | 3 |
| Massachusetts General Hospital | 1 |
By country register
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Ravulizumab trials
How many clinical trials are testing Ravulizumab?
14 current trials in our Italy, Japan, USA, China, Poland, Germany, Spain, South Korea, France, Canada, Taiwan, UK, Austria, Czechia, Brazil, Australia, Netherlands, Belgium, Turkey, Israel, Portugal and Switzerland registers name Ravulizumab (also registered as ALXN1210) as a drug or biological intervention, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.
Are Ravulizumab trials recruiting patients?
Yes. 10 of the 14 trials are recruiting: 4 with sites in Italy, 4 with sites in Japan, 3 with sites in USA, 4 with sites in China, 3 with sites in Poland, 3 with sites in Germany, 2 with sites in Spain, 2 with sites in South Korea, 1 with sites in France, 1 with sites in Canada, 2 with sites in Taiwan, 1 with sites in UK, 1 with sites in Austria, 1 with sites in Czechia, 1 with sites in Brazil, 1 with sites in Australia and 1 with sites in Portugal. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Ravulizumab clinical trials?
Alexion Pharmaceuticals, Inc (10), AstraZeneca (3) and Massachusetts General Hospital (1). The number in brackets is how many trials each organisation leads.
Is Ravulizumab licensed in Ireland?
Yes. The HPRA medicines list includes 2 single-substance products containing Ravulizumab, for example Ultomiris 1 100 mg/11 mL concentrate for solution for infusion (Alexion Europe S.A.S.). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
Is there a Ravulizumab shortage?
Not in the lists we track: Ravulizumab has no entry in the EMA, FDA or German BfArM shortage registers as of their latest sync.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Ravulizumab works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Ravulizumab works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Ravulizumab (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.